Comparative Pharmacology
Head-to-head clinical analysis: GYNE LOTRIMIN 3 versus MYCELEX 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNE LOTRIMIN 3 versus MYCELEX 7.
GYNE-LOTRIMIN 3 vs MYCELEX-7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
Clotrimazole, an azole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
Intravaginal: one applicatorful (5 g of 2% cream) or one suppository (200 mg) once daily at bedtime for 3 days.
Clotrimazole 100 mg vaginal tablet inserted intravaginally once daily at bedtime for 7 days.
None Documented
None Documented
Terminal elimination half-life is 3.5–5 hours for topical administration; systemic absorption is minimal (<0.5%), so half-life reflects local clearance.
The systemic half-life of clotrimazole following vaginal administration is approximately 0.5–1 hour due to rapid metabolism and elimination. This short half-life reflects minimal systemic absorption (3–10%).
Clotrimazole is primarily excreted via feces (biliary elimination) as metabolites, with approximately 0.5% excreted renally as unchanged drug.
Primarily via feces as unchanged drug (approx. 50%) and metabolites. Renal excretion of unchanged drug is minimal (<1%) as the drug is poorly absorbed from the vagina. Biliary excretion contributes to fecal elimination.
Category C
Category C
Azole Antifungal
Azole Antifungal